UK Markets open in 5 hrs 56 mins

Sareum Holdings plc (SAR.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
192.50+12.50 (+6.94%)
At close: 05:09PM BST

Sareum Holdings plc

Langford Arch
Unit 2A London Road Pampisford
Cambridge CB22 3FX
United Kingdom
44 1223 497 700

Full-time employees6

Key executives

NameTitlePayExercisedYear born
Dr. Tim J. Mitchell Ph.D.Founder, CEO & Exec. Director189.41kN/A1960
Dr. John C. Reader Ph.D.Founder, Chief Scientific Officer & Exec. Director187.01kN/A1967
Mr. Anthony Bunn F.C.M.A., FCMASec.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.

Corporate governance

Sareum Holdings plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.